SequelSEC

TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA

Pharmaceutical Preparations · CIK 0000818686 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$14.10B
Fiscal year ended 2026-06-30
Operating income
$1.60B
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$18.16BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$15.79Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income12.9×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue1.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
SBC / revenue0.9%3th
Effective tax rate-14.7%11th
Operating margin12.5%87th
Current ratio1.04x16th
Net margin8.2%82th
Gross margin51.8%29th
Revenue YoY growth4.3%51th

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported revenue of $14.10B and net income of $706.00M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from TEVA PHARMACEUTICAL INDUSTRIES LTD’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

TEVA PHARMACEUTICAL INDUSTRIES LTD income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$14.10B
Cost of revenue$8.23B
Gross profit$9.08B
Operating income$1.60B
Net income$706.00M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income$708.00M
Income tax expense$12.00M
Diluted EPSUnavailable
Selling, general & administrative$4.13B
General & administrative$1.30B
Selling & marketing$2.82B

Balance

TEVA PHARMACEUTICAL INDUSTRIES LTD balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$3.66B
Total assets$39.86B
Current assets$13.76B
Total liabilities$32.10B
Current liabilities$15.65B
Total equity incl. NCI$7.76B
Temporary (mezzanine) equityUnavailable
Inventory$3.22B
Accounts receivable$3.49B
Goodwill$15.84B
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

TEVA PHARMACEUTICAL INDUSTRIES LTD cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$1.90B
Capital expendituresUnavailable
Investing cash flow$38.00M
Financing cash flow-$401.00M
Net change in cash$1.49B
Stock-based compensation$168.00M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$989.00M

Derived

TEVA PHARMACEUTICAL INDUSTRIES LTD derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin64.4%
Operating margin11.4%
FCF marginUnavailable
SBC / revenue1.2%
Current ratio0.88x
Revenue YoY growth-15.2%
Net margin5.0%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rate1.7%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TEVA in the interactive workspace to inspect any figure back to its filing.

Source filings

25-NSE · Filed 2026-09-14View SEC filing
10-Q · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-04-29View SEC filing
10-K · Filed 2026-02-03View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-07-30View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.